Skip to main navigation
Aimmune
  • Contact
Menu CLOSE X
CLOSE X
  • About Us
    • Company Overview
    • History
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
    • Contact
  • Therapeutic Focus
    • Food Allergies
    • CODIT™ & Oral Immunotherapy
    • Helpful Resources
  • Pipeline
    • Development Pipeline
    • AR101 for Peanut Allergy
    • Discovery Program
    • Expanded Access Policy
  • News & Events
    • Press Releases
    • Medical Congresses
    • Media Resources
  • Investor Relations
    • Investor Overview
    • Corporate Presentation
    • Press Releases
    • Events
    • Financials & Filings
      • Annual Reports
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor FAQs
  • Contact

Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress

  • Read more about Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress

Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017

  • Read more about Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017

Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy

  • Read more about Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy

Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th

  • Read more about Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th

Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy

  • Read more about Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy

Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

  • Read more about Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy

Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16

  • Read more about Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16

Aimmune Therapeutics Announces First Quarter 2017 Financial Results

  • Read more about Aimmune Therapeutics Announces First Quarter 2017 Financial Results

Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer

  • Read more about Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer

Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results

  • Read more about Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 1
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Shareholder Tools

  • Print Page
  • Email Alerts
  • IR Contact
  • RSS Feeds
About Us
  • Company Overview
  • History
  • Leadership
  • Board of Directors
  • Scientific Advisory Board
  • Partners
  • Careers
  • Contact
Therapeutic Focus
  • Food Allergies
  • CODIT™ & Oral Immunotherapy
  • Helpful Resources
Pipeline
  • Development Pipeline
  • AR101 for Peanut Allergy
  • Discovery Program
  • Expanded Access Policy
News & Events
  • Press Releases
  • Medical Congresses
  • Media Resources
Investor Relations
  • Investor Overview
  • Corporate Presentation
  • Press Releases
  • Events
  • Financials & Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQs
© 2018 Aimmune Therapeutics.
  • All rights reserved.
  • Terms of Use
  • Twitter Guidelines

Aimmune’s food allergy treatments are investigational and are not FDA-approved.

ShareThis Copy and Paste
Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...